Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318474 · ClinicalTrials.gov registry record · Phase 3
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
A Phase 3 study, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- Terminated
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT00318474 is a Phase 3 study that was terminated before completion, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 184 participants.
The verdict
NCT00318474, a Phase 3 study, was terminated before completion, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of individuals diagnosed with IgAN, including children, will eventually progress to chronic renal insufficiency (CRI) and end stage renal disease (ESRD). The study is to evaluate the safety and benefits of MMF in patients with IgAN who have been pre-treated (and continue to be treated) with angiotensin converting enzyme inhibitors (ACEi) and fish oil supplements (FOS).
Interventions
- DRUG Mycophenolate Mofetil (MMF)
- DRUG MMF Placebo
- DRUG ACEi
- DRUG FOS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2002-01 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318474
The ClinicalTrials.gov registry entry for NCT00318474 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mycophenolate Mofetil (MMF) is the first listed.
NCT00318474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00318474 about?
NCT00318474 is a clinical study titled "Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy". IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of individuals diagnosed with IgAN, including children, will eventually progress to chronic renal insufficiency (CRI) and end stage renal disease (ESRD). The study is to evaluate the safety and benefits of MMF in ...
What is the current status of trial NCT00318474?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2002-01. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00318474?
The interventions under investigation include: Mycophenolate Mofetil (MMF) (DRUG), MMF Placebo (DRUG), ACEi (DRUG), FOS (DRUG).
Who is sponsoring clinical trial NCT00318474?
This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.